194 related articles for article (PubMed ID: 25372392)
1. Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients.
Wang J; Wang X; Zhao M; Choo SP; Ong SJ; Ong SY; Chong SS; Teo YY; Lee CG
PLoS One; 2014; 9(11):e111694. PubMed ID: 25372392
[TBL] [Abstract][Full Text] [Related]
2. Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients.
Marcuello E; Altés A; del Rio E; César A; Menoyo A; Baiget M
Int J Cancer; 2004 Dec; 112(5):733-7. PubMed ID: 15386371
[TBL] [Abstract][Full Text] [Related]
3. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
4. Thymidylate synthase pharmacogenetics in colorectal cancer.
Marsh S; McLeod HL
Clin Colorectal Cancer; 2001 Nov; 1(3):175-8; discussion 179-81. PubMed ID: 12450432
[TBL] [Abstract][Full Text] [Related]
5. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E
Int J Cancer; 2011 Apr; 128(8):1935-45. PubMed ID: 20560137
[TBL] [Abstract][Full Text] [Related]
6. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
Johnston PG; Benson AB; Catalano P; Rao MS; O'Dwyer PJ; Allegra CJ
J Clin Oncol; 2003 Mar; 21(5):815-9. PubMed ID: 12610179
[TBL] [Abstract][Full Text] [Related]
7. Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Okazaki S; Schirripa M; Loupakis F; Cao S; Zhang W; Yang D; Ning Y; Berger MD; Miyamoto Y; Suenaga M; Iqubal S; Barzi A; Cremolini C; Falcone A; Battaglin F; Salvatore L; Borelli B; Helentjaris TG; Lenz HJ
Cancer; 2017 Nov; 123(22):4506-4514. PubMed ID: 28708932
[TBL] [Abstract][Full Text] [Related]
8. The relationship between 5-fluorouracil sensitivity and single nucleotide polymorphisms of the orotate phosphoribosyl transferase gene in colorectal cancer.
Kitajima M; Takita N; Hata M; Maeda T; Sakamoto K; Kamano T; Ochiai T
Oncol Rep; 2006 Jan; 15(1):161-5. PubMed ID: 16328050
[TBL] [Abstract][Full Text] [Related]
9. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.
Kjersem JB; Ikdahl T; Lingjaerde OC; Guren T; Tveit KM; Kure EH
Mol Oncol; 2014 Feb; 8(1):59-67. PubMed ID: 24119443
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
Kim ST; Choi YJ; Park KH; Oh SC; Seo JH; Shin SW; Kim JS; Kim YH
Asia Pac J Clin Oncol; 2011 Mar; 7(1):82-7. PubMed ID: 21332655
[TBL] [Abstract][Full Text] [Related]
11. Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?
Marcuello E; Altés A; Menoyo A; Rio ED; Baiget M
Cancer Chemother Pharmacol; 2006 Jun; 57(6):835-40. PubMed ID: 16187112
[TBL] [Abstract][Full Text] [Related]
12. Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy.
Watson RG; Muhale F; Thorne LB; Yu J; O'Neil BH; Hoskins JM; Meyers MO; Deal AM; Ibrahim JG; Hudson ML; Walko CM; McLeod HL; Auman JT
Eur J Cancer; 2010 Dec; 46(18):3358-64. PubMed ID: 20727737
[TBL] [Abstract][Full Text] [Related]
13. Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer.
Huang X; Ke K; Jin W; Zhu Q; Zhu Q; Mei R; Zhang R; Yu S; Shou L; Sun X; Feng J; Duan T; Mou Y; Xie T; Wu Q; Sui X
Front Immunol; 2022; 13():887048. PubMed ID: 35784334
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells.
Nishida N; Yamashita S; Mimori K; Sudo T; Tanaka F; Shibata K; Yamamoto H; Ishii H; Doki Y; Mori M
Ann Surg Oncol; 2012 Sep; 19(9):3065-71. PubMed ID: 22322955
[TBL] [Abstract][Full Text] [Related]
15. Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer.
Ide T; Kitajima Y; Ohtaka K; Mitsuno M; Nakafusa Y; Miyazaki K
Oncol Rep; 2008 Jun; 19(6):1571-6. PubMed ID: 18497967
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.
Andreou A; Kopetz S; Maru DM; Chen SS; Zimmitti G; Brouquet A; Shindoh J; Curley SA; Garrett C; Overman MJ; Aloia TA; Vauthey JN
Ann Surg; 2012 Oct; 256(4):642-50. PubMed ID: 22968062
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of infusional biomodulated 5-fluorouracil in metastatic colorectal cancer after raltitrexed failure.
Decoster L; Neyns B; Akouaouach H; Fontaine C; Schallier D; De Grève JL
Anticancer Res; 2004; 24(3b):2037-40. PubMed ID: 15274397
[TBL] [Abstract][Full Text] [Related]
18. FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.
Nakanishi R; Kitao H; Fujinaka Y; Yamashita N; Iimori M; Tokunaga E; Yamashita N; Morita M; Kakeji Y; Maehara Y
Ann Surg Oncol; 2012 Oct; 19(11):3627-35. PubMed ID: 22526901
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of cisplatin and dacarbazine for metastatic colorectal carcinoma resistant to 5-fluorouracil.
Içli F; Arican A; Cay F; Akbulut H; Dinçol D; Karaoğuz H; Demirkazik A
Oncology; 1999; 56(4):297-300. PubMed ID: 10343193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
